

Curriculum vitae with track record (for researchers)

* ROLE IN THE PROJECT	
------------------------------	--

Personal information

First name, Surname:	Kurt Hanevik		
Date of birth:	1968	Sex:	Male
Nationality:	Norwegian		
Researcher unique identifier(s) (ORCID, ResearcherID, etc.):	ORCID 000-0002-1466-2326		
URL for personal website:	http://www.uib.no/personer/Kurt.Hanevik		

Education

Year	Faculty/department - University/institution - Country
2012	Ph.D. dissertation, University of Bergen, Norway
2013	Medical doctor specialist of infectious diseases - Haukeland University Hospital, Norway
2008	Medical doctor specialist of internal medicine - Haukeland University Hospital, Norway
1999	Diploma in Tropical Medicine and Hygiene (DTMH) – LSHTM, London, UK
1996	MD – University of Bergen, Norway

Positions - current and previous

(Academic sector/research institutes/industrial sector/public sector/other)

Year	Job title – Employer - Country
2021 ->	Professor – University of Bergen, Norway
2007 ->	Consultant – Norwegian National advisory unit for tropical infectious diseases - Haukeland University Hospital - Norway
2012 – 2020	Post doc / Researcher / Assoc. professor - University of Bergen
2008-2012	PhD-candidate – University of Bergen, Norway
1999 - 2000	Work with MSF in West Papua, Indonesia and Taloqan, Afghanistan
1996-2008	Medical doctor at Alesund Regional Hospital and Haukeland University Hospital

FELLOWSHIPS, AWARDS AND PRIZES (if applicable)

	Name of institution/country
2015	One year fellowship from HelseVest to visit Center for Vaccine development, University of Maryland, Baltimore, USA
2013	PhD of the year (2012), Faculty of Medicine and Dentistry, University of Bergen, 9000€.
2008	Norwegian Gastroenterology Association - Prize for best clinical study from a university clinic for “ <i>Persisting abdominal symptoms after Giardia-infection</i> (oral presentation)”. Lillehammer. 1 000€.
2007	Digestive Diseases Week - Poster of distinction for “ <i>Persisting abdominal symptoms after Giardia infection – A post-infectious functional bowel disorder?</i> ” Poster, Washington, USA

MOBILITY (if applicable)

Research stays abroad lasting more than three months

	Name of faculty/department/centre, name of university/institution/country
2015	12 months visiting researcher to Centre for Vaccine Development, University of Maryland, USA

Project management experience

(Academic sector/research institutes/industrial sector/public sector/other. Please list the most relevant.)

Year	Project owner - Project - Role - Funder
2022	Haukeland University Hospital - Bacterial strain colonization in fecal microbiota transfer therapy in patients with irritable bowel syndrome – PI – Western Regional Health Authority
2016-2023	University of Bergen - A Randomized Controlled trial of the effect of deferring BCG vaccination to 14 weeks of age in HIV-1 exposed infants in Uganda - immunology substudy – PI – Norwegian Research Council via Centre for Intervention Science in Maternal and Child Health
2016 - 2022	University of Bergen - LED microscopy for Cryptosporidium testing in children in low-income countries – Main supervisor – Norwegian Research Council / BMGF
2000-2001	Doctors without Borders – Public health in Afghanistan - Field coordinator – MSF

Supervision of students

(Total number of students)

Master's students	Ph.D. students	University/institution - Country
11	3	Completed at University of Bergen – Norway
3	3	Ongoing at University of Bergen – Norway

TEACHING ACTIVITIES (if applicable)

	Teaching position – topic, name of university/institution/country
2021 ->	Microbiology courses for medical-, dentistry-, and dental assistant students
2001	Various courses at UiB, Haukeland University Hospital and for Dnlf on tropical medicine, Parasitology, War & Health, diarrheal diseases, Malaria, bacteriology

ORGANISATION OF MEETINGS (if applicable)

	Role and name of event/number of participants/country
2022	Workshop leader for “Cellular immunity and immunological memory in ETEC and Shigella” at Vaccines against Shigella and ETEC (VASE) meeting, 300 participants, Washington, USA
2021	Track leader of track 3 and chair of several sessions on neglected tropical diseases at European conference on Tropical Medicine and International Health, 1100 participants, Digital conference, September 2021, Bergen, Norway

Other relevant professional experiences

(E.g. institutional responsibilities, organisation of scientific meetings, membership in academic societies, review boards, advisory boards, committees, major research or innovation collaborations, other commissions of trust in public or private sector)

Year	Description - Role
2023	Member of European Society for Clinical Microbiology and Infectious Diseases Scientific Affairs Subcommittee
2022	Member, Scientific Advisory Board, Armauer Hansen Research Institute, Ethiopia
2014 -2022	Opponent at four PhD dissertations
2016 - 2023	Grant reviewer for Helse-Nord regional health agency, EU Marie Curie program, Austrian APPEAR programs and for Independent research fund Denmark (DFF)
2015 -2019	National delegate, EU COST action: Foodborne parasites (Euro-FDP) (FA1408)
2012 - 2016	National delegate, EU COST action: Genetics in irritable bowel syndrome (GENIEUR) (BM1106)
2003 - 2005	Norwegian Board, Doctors without borders (MSF)
1999-2001	Doctors without borders emergency/public health projects in Papua New Guinea (Wamena) and in Afghanistan (Taloqan/Mazar-i-Sharif)

Publications in peer-reviewed journals

h-index: 23 - Web of Science

Level 2 journals and first and last authorships in **bold**

29 - Google Scholar

Total 85 published articles. 19 last authorships, 17 first authorships, 13 second authorships. 7 articles with first or last authorship in level 2 journals.

Publications last 7 years (since September 2016)

41. **Hanevik K. Giardia lamblia - pathogen or commensal? Clin Infect Dis. 2016; 63(6):798-9 (Editorial commentary)**
42. Jørgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, Jørgensen KK, Osnes LT, Bratlie J, Eide TJ, Dahl CP, Holter E, Tronstad RR, Hanevik K, Brattbakk HR, Kaveh F, Fiskerstrand T, Kran AB, Ueland T, Karlsen TH, Aukrust P, Lundin KE, Fevang B. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency. *Am J Gastroenterol.* 2016 Oct;111(10):1467-1475
43. **Hanevik K**, Kristoffersen E, Mørch K, Rye KP, Sørnes S, Svård S, Bruserud Ø, Langeland N. Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. *BMC Immunol.* 2017 Jan 28;18(1):5.
44. **Moyo SJ, Kommedal Ø, Blomberg B, Hanevik K, Gjerde Tellevik M, Maselle SY, Langeland N. Comprehensive analysis of prevalence, epidemiological and clinical characteristics of mono-infections and co-infections in diarrhoeal diseases in children in Tanzania. Am J Epidemiol. 2017 Nov 1;186(9):1074-1083**
45. Radunovic M, Klotz C, Saghaug CS, Brattbakk HR, Aebischer T, Langeland N, **Hanevik K**. Genetic variation in potential Giardia vaccine candidates cyst wall protein 2 and α 1-giardin. *Parasitol Res.* 2017 Aug;116(8):2151-2158.
46. Litleskare S, Rortveit G, Eide GE, Hanevik K, Langeland N, Wensaas KA. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years after Giardia Infection. *Clin Gastroenterol Hepatol.* 2018 Jul;16(7):1064-1072.
47. Escobedo AA, Almirall P, Hanevik K, Cimerman S, Rodríguez-Morales AJ, Almanza C, Auza-Santivañez J. Giardiasis: a diagnosis that should be considered regardless of the setting. *Epidemiol Infect.* 2018 Jul;146(10):1216-1218. (Opinion article)
48. **Hanevik K**, Wik E, Langeland N, Hausken T. Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection. *Scand J Gastroenterol.* 2018 Jun-Jul;53(7):809-812.
49. Hjøllø T, Bratland E, Steinsland H, Radunovic M, Langeland N, **Hanevik K**. Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area. *Exp Parasitol.* 2018 Aug;191:66-72.
50. Lalle M, **Hanevik K**. Treatment-refractory giardiasis: challenges and solutions. *Infection and Drug Resistance.* 2018 Oct;11:1921-1933 (Review)
51. Vedøy OB, Hanevik K, Sakkestad ST, Sommerfelt H, Steinsland H. Proliferation of enterotoxigenic Escherichia coli strain TW11681 in stools of experimentally infected human volunteers. *Gut Pathog.* 2018 Oct 16;10:46..
52. Tronstad R, Polushina T, Brattbakk HR, Stansberg S, von Volkmann H, Hanevik K, Ellinghaus E, Jørgensen SF, Erslund KM, Pham KDC, Gilja OH, Hovdenak N, Hausken T, Vatn MH, Franke A, Knappskog PA, Karlsen TH, Hellard SL, Fiskerstrand T. Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea. *Scand J Gastroenterol.* 2018 Oct - Nov;53(10-11):1264-1273.
53. **Dizdar V, Hausken T, Larum OD, Gilja OH, Langeland N, Hanevik K. Prolonged duodenal mucosal lymphocyte alterations in patients with and without post infectious functional gastrointestinal disorders after Giardia infection. 2019 Jun 19;220(2):321-329**
54. **Hanevik K**, Chen WH, Talaat KR, Porter C, Bourgeois L. The way forward for ETEC controlled human infection models (CHIMs). *Vaccine.* 2019 Aug 7;37(34):4794-4799. (Review)
55. Litleskare S, Rortveit G, Eide GE, Emberland KE, Hanevik K, Langeland N, Wensaas KA. Quality of life and its association with irritable bowel syndrome and fatigue ten years after giardiasis. *Neurogastroenterol Motil.* 2019 Feb 14:e13559

56. Davids BJ, Liu CM, Hanson EM, Le CHY, Ang J, Hanevik K, Fischer M, Radunovic M, Langeland N, Ferella M, Svärd SG, Ghassemian M, Miyamoto Y, Eckmann L. Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of *Giardia lamblia*. *Infect Immun*. 2019 May 21;87(6). pii: e00219-19.
57. Saghaug CS, Klotz C, Kallio JP, Brattbakk HR, Stokowy T, Aebischer T, Kursula I, Langeland N, **Hanevik K**. Genetic variation in metronidazole metabolism and oxidative stress pathways in clinical *Giardia* assemblage A and B isolates. *Infect Drug Resist*. 2019 May 10;12:1221-1235.
58. Todnem Sakkestad S, Steinsland H, Skrede S, Kleppa E, Lillebø K, Sævik M, Søyland H, Rykkje Heien A, Gjerde Tellevik M, Barry EM, Sommerfelt H, **Hanevik K**. Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing ETEC Strain TW11681. *Pathogens*. 2019 Jun 22;8(2). pii: E84.
59. Haanshuus CG, Mørch K, Blomberg B, Strøm GEA, Langeland N, Hanevik K, Mohn SC. Assessment of malaria real-time PCR methods and application with focus on low-level parasitaemia. *PLoS One*. 2019 Jul 5;14(7):e0218982.
60. Zangenberg M, Johansen ØH, Abdissa A, Eshetu B, Kurtzhals JAL, Friis H, Sommerfelt H, Langeland N, **Hanevik K**. Prolonged and persistent diarrhoea is not restricted to children with acute malnutrition: an observational study in Ethiopia. *Trop Med Int Health*. 2019 Jul 20.
61. Sakkestad ST, Skavland J, **Hanevik K**. Whole blood preservation methods alter chemokine receptor detection in mass cytometry experiments. *J Immunol Methods*. 2019 Oct 17:112673
62. Sakkestad ST, Steinsland H, Skrede S, Lillebø K, Skutlaberg DH, Guttormsen AB, Zavialov A, Paavilainen S, Søyland H, Sævik M, Heien AR, Tellevik MG, Barry E, Langeland N, Sommerfelt H, **Hanevik K**. A new human challenge model for testing heat-stable toxin-based vaccine candidates for enterotoxigenic *Escherichia coli* diarrhea - dose optimization, clinical outcomes, and CD4+ T cell responses. *PLoS Negl Trop Dis*. 2019 Oct 30;13(10):e0007823.
63. Namakula R, de Bree LCJ, A Tvedt TH, Netea MG, Cose S, **Hanevik K**. Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β -glucan. *PLoS One*. 2020 Feb 21;15(2):e0229287.
64. von Volkmann HL, Brønstad I, Tronstad RR, Dizdar V, Nylund K, Hanevik K, Hausken T, Gilja OH, Fiskerstrand T. Plasma levels of guanylin are reduced in patients with Crohn's disease. *Scand J Gastroenterol*. 2020 Apr 20:1-5.
65. Martínez C, Lasitschka F, Thöni C, Wohlfarth C, Braun A, Granzow M, Röth R, Dizdar V, Rappold GA, Hausken T, Langeland N, Hanevik K, Niesler B. Comparative expression profiling in the intestine of patients with *Giardia*-induced postinfectious functional gastrointestinal disorders. *Neurogastroenterol Motil*. 2020 May 11:e13868.
66. Mørch K & **Hanevik K**. Giardiasis treatment: An update with a focus on refractory disease. *Current Opinion in Infectious Diseases*. (Review) Accepted July 2020
67. Riaz S, Steinsland H, **Hanevik K**. Human Mucosal IgA Immune Responses against Enterotoxigenic *Escherichia coli*. *Pathogens*. 2020;9(9):E714.
68. Cox E, Aloulou M, Fleckenstein JM, Schäffer C, Sjöling Å, Schüller S, Hanevik K, Devriendt B, Zhang W, Svennerholm AM, Dudley EG. The Intriguing Interaction of *Escherichia coli* with the Host Environment and Innovative Strategies to Interfere with Colonization: a Summary of the 2019 *E. coli* and Mucosal Immune System Meeting. *Appl Environ Microbiol*. 2020 Nov 24;86(24)
69. Moyo SJ, Manyahi J, Blomberg B, Tellevik MG, Masoud NS, Aboud S, Manji K, Roberts AP, Hanevik K, Mørch K, Langeland N. Bacteraemia, Malaria, and Case Fatality Among Children Hospitalized With Fever in Dar es Salaam, Tanzania. *Front Microbiol*. 2020 Sep 10;11:2118.
- 70. Johansen ØH, Abdissa A, Zangenberg M, Mekonnen Z, Eshetu B, Bjørang O, Alemu Y, Sharew B, Langeland N, Robertson LJ, Hanevik K. Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study. *Lancet Infect Dis*. 2020 Dec 3:S1473-3099(20)30556-9.**
71. Saghaug CS, Klotz C, Kallio JP, Aebischer T, Langeland N, **Hanevik K**. Genetic Diversity of the Flavohemoprotein Gene of *Giardia lamblia*: Evidence for High Allelic Heterozygosity and Copy Number Variation. *Infect Drug Resist*. 2020 Dec 18;13:4531-4545.
72. Mortensen N, Jonasson SA, Lavesson IV, Emberland KE, Litleskare S, Wensaas KA, Rortveit G, Langeland N, **Hanevik K**. Characteristics of hospitalized patients during a large waterborne outbreak of *Campylobacter jejuni* in Norway. *PLoS One*. 2021 Mar 23;16(3):e0248464.

73. Emberland KE, Wensaas KA, Litleskare S, Iversen A, Hanevik K, Langeland N, Rortveit G. Clinical features of gastroenteritis during a large waterborne *Campylobacter* outbreak in Askøy, Norway. *Infection*. 2022 Apr;50(2):343-354.
74. Riaz S, Steinsland H, Thorsing M, Andersen AZ, Boysen A, **Hanevik K**. Characterization of Glycosylation-Specific Systemic and Mucosal IgA Antibody Responses to *Escherichia coli* Mucinase YghJ (SslE). *Front Immunol*. 2021 Dec 17;12:760135.
75. Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, Moutsianas L, Holliday J, Shi J, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet*. 2021 Nov;53(11):1543-1552.
76. Campbell SM, Pettersen FO, Brekke H, Hanevik K, Robertson LJ. Transition to PCR diagnosis of cryptosporidiosis and giardiasis in the Norwegian healthcare system: could the increase in reported cases be due to higher sensitivity or a change in the testing algorithm? *Eur J Clin Microbiol Infect Dis*. 2022 May;41(5):835-839.
77. **Hanevik K**, Saghaug C, Aaland M, Morch K, Langeland N. No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after *Giardia* infection. *JGH Open*. 2022 Mar 14;6(3):185-188.
78. Ihara S, Miyamoto Y, Le CHY, Tran VN, Hanson EM, Fischer M, Hanevik K, Eckmann L. Conserved metabolic enzymes as vaccine antigens for giardiasis. *PLoS Negl Trop Dis*. 2022 Apr 25;16(4):e0010323.
79. Johansen ØH, Abdissa A, Zangenberg M, Mekonnen Z, Eshetu B, Sharew B, Moyo S, Sommerfelt H, Langeland N, Robertson LJ, **Hanevik K**. A comparison of risk factors for cryptosporidiosis and non-cryptosporidiosis diarrhoea: A case-case-control study in Ethiopian children. *PLoS Negl Trop Dis*. 2022 Jun 6;16(6):e0010508.
80. Johansen ØH, Abdissa A, Bjørang O, Zangenberg M, Sharew B, Alemu Y, Moyo S, Mekonnen Z, Langeland N, Robertson LJ, **Hanevik K**. Oocyst Shedding Dynamics in Children with Cryptosporidiosis: a Prospective Clinical Case Series in Ethiopia. *Microbiol Spectr*. 2022 Aug 31;10(4):e0274121.
81. Saghaug CS, Gamlem AL, Hauge KB, Vahokoski J, Klotz C, Aebischer T, Langeland N, **Hanevik K**. Genetic diversity in the metronidazole metabolism genes nitroreductases and pyruvate ferredoxin oxidoreductases in susceptible and refractory clinical samples of *Giardia lamblia*. *Int J Parasitol Drugs Drug Resist*. 2023 Apr;21:51-60.
82. Vedøy OB, Steinsland H, Sakkestad ST, Sommerfelt H, **Hanevik K**. Strong Association between Diarrhea and Concentration of Enterotoxigenic *Escherichia coli* Strain TW10722 in Stools of Experimentally Infected Volunteers. *Pathogens*. 2023 Feb 8;12(2):283
83. Klotz C, Schmid MW, Winter K, Ignatius R, Weisz F, Saghaug CS, Langeland N, Dawson S, Lalle M, Hanevik K, Cacciò SM, Aebischer T. Highly contiguous genomes of human clinical isolates of *Giardia duodenalis* reveal assemblage- and sub-assemblage-specific presence-absence variation in protein-coding genes. *Microb Genom*. 2023 Mar;9(3):mgen000963.
- 84. Rim S, Sakkestad ST, Zhou F, Gullaksen SE, Skavland J, Chauhan SK, Steinsland H, Hanevik K. Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic *Escherichia coli* infection. *Eur J Immunol*. 2023 Apr 27:e2250254.**
85. Brønstad I, von Volkmann HL, Sakkestad ST, Steinsland H, **Hanevik K**. Reduced Plasma Guanylin Levels Following Enterotoxigenic *Escherichia coli*-Induced Diarrhea. *Microorganisms*. 2023 Aug 3;11(8):1997